1195.5000 62.30 (5.50%)
NSE Jun 01, 2026 15:31 PM
Volume: 118.1K
 

1195.50
5.50%
Deven Choksey
We expect the company to grow its Revenue/EBITDA/PAT at a CAGR of 25% / 46.9% / 57.5% for the period of FY26-FY28E. The company is currently trading at 28x FY28E and we value the company at a PE of 32x FY28E EPS, implying a target price of INR 1,426 with the upside of 12.2%.
Tatva Chintan Pharma.. has an average target of 1690.50 from 2 brokers.
More from Tatva Chintan Pharma Chem Ltd.
Recommended